Halila H, Huhtala M L, Schröder T, Kiviluoto T, Stenman U H
Clin Chim Acta. 1985 Dec 31;153(3):209-16. doi: 10.1016/0009-8981(85)90354-7.
Pancreatic secretory trypsin inhibitor (PSTI) is a 6000-dalton peptide, that occurs in high concentrations in the pancreas and in pancreatic juice. It is thought to be synthesized by pancreatic acinar cells. We have recently reported the findings of an identical trypsin inhibitor at high concentrations in the urine of patients with gynecological malignancy. Therefore, we have named the inhibitor tumor-associated trypsin inhibitor (TATI). We have now studied patients who have undergone total pancreatoduodenectomy for pancreatic cancer or chronic pancreatitis. By radioimmunoassay (RIA), we found normal levels of this inhibitor in the serum and urine of pancreatectomized patients. The absence of pancreas was confirmed by measuring serum trypsin. By gel filtration and HPLC it was found that PSTI/TATI occurring in pancreatectomized patients was indistinguishable from that found in connection with pancreatitis and ovarian cancer.
胰腺分泌性胰蛋白酶抑制剂（PSTI）是一种6000道尔顿的肽，在胰腺和胰液中浓度很高。它被认为是由胰腺腺泡细胞合成的。我们最近报道了在妇科恶性肿瘤患者尿液中发现高浓度的一种相同的胰蛋白酶抑制剂。因此，我们将该抑制剂命名为肿瘤相关胰蛋白酶抑制剂（TATI）。我们现在研究了因胰腺癌或慢性胰腺炎接受全胰十二指肠切除术的患者。通过放射免疫测定（RIA），我们发现胰腺切除患者的血清和尿液中该抑制剂水平正常。通过测量血清胰蛋白酶证实胰腺已缺失。通过凝胶过滤和高效液相色谱法发现，胰腺切除患者体内的PSTI/TATI与胰腺炎和卵巢癌患者体内发现的无法区分。
